The influence of molecular structure on the affinity and efficacy of some beta-adrenoceptor agonists
- PMID: 2868416
- DOI: 10.1007/BF00634244
The influence of molecular structure on the affinity and efficacy of some beta-adrenoceptor agonists
Abstract
The affinity and efficacy of a number of sympathomimetic amines structurally related to prenalterol and the selective beta 1-adrenoceptor agonist RO363 were determined using a combination of radioligand binding and organ bath techniques. Affinity of the molecules (pKD) was calculated from their ability to displace the radioligand [125I]iodocyanopindolol ([125I]CYP) from beta-adrenoceptor sites in left atrial (beta 1) and uterine (beta 2) membrane homogenates. These pKD values were used to calculate efficacy from the positive inotropic and uterine relaxant responses elicited by the drugs in organ bath experiments. The drugs studied were either arylethanolamines i.e., (-)-isoprenaline (ISO), p-hydroxyisoprenaline (pOH-ISO), compounds XIV and XVI or aryloxypropanolamine-derivatives, i.e., oxymethylene-isoprenaline (OM-ISO), prenalterol and Compound XI which possessed a p-phenol or catechol ring and an isopropyl or a homoveratryl amine substituent. Only ISO, OM-ISO, pOH-ISO and Compound XVI were active as agonists in both tissue preparations. These drugs were partial agonists which exhibited a wide range of pD2 values and did not display any marked selectivity for either beta-adrenoceptor subtype. Compound XI and prenalterol were inactive as agonists and together with the partial agonists behaved as competitive antagonists to ISO in the two preparations. All drugs tested displaced [125I]CYP from beta-adrenoceptor sites, however, there was also a wide range of potency amongst the drugs. Analysis of the structure-affinity and structure-efficacy relationships indicated that removal of the 3-hydroxyl group from the catechol ring reduces both affinity and efficacy without altering the selectivity of the drug for either beta-adrenoceptor subtype.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
The affinity and efficacy of the selective beta 1-adrenoceptor stimulant RO363 at beta 1- and beta 2-adrenoceptor sites.Br J Pharmacol. 1984 Aug;82(4):897-904. doi: 10.1111/j.1476-5381.1984.tb16488.x. Br J Pharmacol. 1984. PMID: 6148117 Free PMC article.
-
Influence of assay buffer on dissociation constants of drugs at beta-adrenoceptor subtypes.Eur J Pharmacol. 1985 Dec 10;119(1-2):93-100. doi: 10.1016/0014-2999(85)90326-7. Eur J Pharmacol. 1985. PMID: 2867924
-
Theoretical and practical problems with the assessment of intrinsic efficacy of agonists: efficacy of reputed beta-1 selective adrenoceptor agonists for beta-2 adrenoceptors.J Pharmacol Exp Ther. 1982 Nov;223(2):416-23. J Pharmacol Exp Ther. 1982. PMID: 6127403
-
The in vitro pharmacology of xamoterol (ICI 118,587).Br J Pharmacol. 1985 May;85(1):179-87. doi: 10.1111/j.1476-5381.1985.tb08845.x. Br J Pharmacol. 1985. PMID: 2862938 Free PMC article.
-
The importance of interactions with helix 5 in determining the efficacy of β-adrenoceptor ligands.Biochem Soc Trans. 2013 Feb 1;41(1):159-65. doi: 10.1042/BST20120228. Biochem Soc Trans. 2013. PMID: 23356277 Review.
Cited by
-
Desensitization and functional antagonism by beta-adrenoceptor and muscarinic receptor agonists, respectively: a comparison with receptor alkylation for calculation of apparent agonist affinity.Br J Pharmacol. 1991 Aug;103(4):1951-7. doi: 10.1111/j.1476-5381.1991.tb12358.x. Br J Pharmacol. 1991. PMID: 1680517 Free PMC article.